Sarepta Announces Results From SRP-9001 Study

Sarepta News Banner

Sarepta today announced topline results from Part 2 of Study 102, an ongoing, randomized, double-blind, placebo-controlled clinical trial evaluating its investigational gene transfer therapy SRP-9001 in Duchenne patients.  

In its placebo crossover cohort, the mean NSAA at 48 weeks scored a statistically significant 2.0 points higher than an external control comparison group of Duchenne patients, and the safety profile of SRP-9001 was consistent with that seen in Part 1. There were no treatment-related serious adverse events, no deaths, and no study discontinuations due to an adverse event. 

This study is ongoing, and all participants continue to be monitored for safety and longer-term assessments of functional outcomes.

For more information, read the press release here.

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.